New Delhi: India’s ‘first’ indigenous Covid-19 vaccine Covaxin, developed by Hyderabad-based vaccine manufacturer Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is all set to begin human clinical trials.
The Central Drugs Standard Control Organisation (CDSCO) had granted the company permission to initiate Phase I and II human clinical trials on 29 June, after it submitted results generated from pre-clinical studies, demonstrating the vaccine’s safety and immune response to the infection.
Recently, ICMR Director-General Dr Balram Bhargava also wrote to the principle investigators in the Covaxin trial asking for the vaccine to be launched by 15 August, triggering a massive controversy about how the timeline would be shrunk. Earlier, the company had submitted that the trials will be conducted over 15 months.
As Covaxin gears up for human trials, here are some details about the vaccine and how it works.
An ‘inactivated’ vaccine
Vaccines can broadly be categorised into two types — inactivated and live vaccines.
Bharat Biotech’s Covaxin vaccine falls under the category of inactivated vaccines.
We are deeply grateful to our readers & viewers for their time, trust and subscriptions.
Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.
In such vaccines, the pathogen is ‘deactivated’ so that it can no longer cause infection. However, parts of the virus can still be identified by the body’s immune system and can trigger an immune reaction.
Hepatitis A, influenza, and polio vaccines used in India are some examples of inactivated vaccines.
Conversely, live attenuated vaccines carry a live but extremely weakened pathogen which cannot cause the disease, such as the measles or the Bacillus Calmette–Guérin vaccine, used primarily against tuberculosis.
Inactivated vaccines are not as powerful as live ones and typically require booster shots. However, the inactive pathogen cannot replicate in the vaccinated person, making it safer for people with an impaired immune system response.
Once the vaccine is administered, the body produces antibodies that can fight off the novel coronavirus infection.
Influenza vaccine — first successful inactivated vaccine
The first inactivated vaccines were developed by Daniel Elmer Salmon and Theobald Smith in the US and the Pasteur Institute group in France. Inactivation was first applied to pathogens such as typhoid, plague, and cholera bacilli.
The first successful inactivated vaccine was developed for influenza in the 1930s.
An inactivated vaccine, also referred to as killed vaccines, can either carry the entire killed pathogen, such as the rabies or influenza vaccines, or be a subunit vaccine, which contains parts of a pathogen which successfully triggers immune reaction in the body.
Hepatitis B and Human papillomavirus (HPV) vaccines are subunit vaccines.
However, it is unclear which category the Covaxin vaccine falls under.
Furthermore, since most Covid vaccines under development use the spike protein of the virus to trigger the production of antibodies, Covaxin is also expected to do the same.
The spike protein of SARS-CoV-2 helps the virus latch onto and infect human cells.
To develop the vaccine, scientists at Bharat Biotech have used a SARS-CoV-2 strain that was isolated at the National Institute of Virology in Pune.
News media is in a crisis & only you can fix it
You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.
You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.
We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.
At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.
This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.
If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.